Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023

- 13 June 2023 - 1 mins read

Aggregated presentation by day and by market

Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Aggregated daily volume (in number of shares) Volume quotidien agrégé (en nombre d’actions) Daily weighted average price of the purchased shares * Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 05/06/2023 FR0010259150 466 111.85 AQEU
IPSEN 549300M6SGDPB4Z94P11 05/06/2023 FR0010259150 443 112.02 CEUX
IPSEN 549300M6SGDPB4Z94P11 05/06/2023 FR0010259150 108 111.72 TQEX
IPSEN 549300M6SGDPB4Z94P11 05/06/2023 FR0010259150 2,083 111.70 XPAR
IPSEN 549300M6SGDPB4Z94P11 06/06/2023 FR0010259150 39 113.17 AQEU
IPSEN 549300M6SGDPB4Z94P11 06/06/2023 FR0010259150 142 112.50 CEUX
IPSEN 549300M6SGDPB4Z94P11 06/06/2023 FR0010259150 2,519 112.94 XPAR
IPSEN 549300M6SGDPB4Z94P11 07/06/2023 FR0010259150 204 112.49 AQEU
IPSEN 549300M6SGDPB4Z94P11 07/06/2023 FR0010259150 497 113.10 CEUX
IPSEN 549300M6SGDPB4Z94P11 07/06/2023 FR0010259150 30 111.70 TQEX
IPSEN 549300M6SGDPB4Z94P11 07/06/2023 FR0010259150 2,469 112.32 XPAR
IPSEN 549300M6SGDPB4Z94P11 08/06/2023 FR0010259150 1,093 110.90 AQEU
IPSEN 549300M6SGDPB4Z94P11 08/06/2023 FR0010259150 1,261 110.63 CEUX
IPSEN 549300M6SGDPB4Z94P11 08/06/2023 FR0010259150 554 110.50 TQEX
IPSEN 549300M6SGDPB4Z94P11 08/06/2023 FR0010259150 5,292 110.56 XPAR
IPSEN 549300M6SGDPB4Z94P11 09/06/2023 FR0010259150 1,220 111.11 AQEU
IPSEN 549300M6SGDPB4Z94P11 09/06/2023 FR0010259150 2,031 111.13 CEUX
IPSEN 549300M6SGDPB4Z94P11 09/06/2023 FR0010259150 298 111.11 TQEX
IPSEN 549300M6SGDPB4Z94P11 09/06/2023 FR0010259150 2,451 111.06 XPAR
             
* Two-digit rounding after the decimal   TOTAL 23,200 111.41  

Attachment

Related Press Releases

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
20 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023
Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
16 June 2023 6 mins read

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
16 June 2023 4 mins read

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
13 June 2023 8 mins read

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
09 June 2023 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital